(Q42718689)

5 November 2017

Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification (English)

1 reference

5 November 2017

2

1 reference

5 November 2017

Alison Millson

1

1 reference

5 November 2017

Leah Hartung

3

1 reference

5 November 2017

Steve Kunitake

4

1 reference

5 November 2017

Ann Bennett

5

1 reference

5 November 2017

Mary C Lowry Nordberg

6

1 reference

5 November 2017

Wedad Hanna

7

1 reference

5 November 2017

Carl T Wittwer

8

1 reference

5 November 2017

Arun Seth

9

1 reference

5 November 2017

Elaine Lyon

10

1 reference

5 November 2017

1 August 2003

1 reference

The Journal of Molecular Diagnostics

5 November 2017

1 reference

5 November 2017

5

1 reference

5 November 2017

3

1 reference

5 November 2017

184-190

1 reference

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status

5 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2, and N-myc measured by quantitative PCR with a multiple competitor template.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Overexpression of the c-erbB-2 protein in human breast tumor cell lines

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

DNA extraction with organic solvents in gel barrier tubes.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1907331

HER-2/neu amplification predicts poor survival in node-positive breast cancer

27 May 2018

1 reference

12 December 2020

Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells

1 reference

12 December 2020

Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer

1 reference

12 December 2020

Continuous fluorescence monitoring of rapid cycle DNA amplification

1 reference

12 December 2020

Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR

1 reference

12 December 2020

Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer

1 reference

12 December 2020

Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization

1 reference

12 December 2020

Color multiplexing hybridization probes using the apolipoprotein E locus as a model system for genotyping

1 reference

12 December 2020

Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis

1 reference

12 December 2020

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

1 reference

12 December 2020

Mutation detection using fluorescent hybridization probes and melting curve analysis

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS1525-1578%2810%2960471-0

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/S1525-1578(10)60471-0

1 reference

5 November 2017

1 reference

5 November 2017

PubMed publication ID

12876209

1 reference